Unknown

Dataset Information

0

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms.


ABSTRACT: Comparisons between everolimus and sunitinib regarding their efficacy and safety in neuroendocrine neoplasms (NENs) are scarce. We retrospectively analysed the clinicopathological characteristics and outcomes in 92 patients with well-differentiated (WD) NEN of different origin (57 pancreatic NENs (PanNENs)), treated with molecular targeted therapy (MTT) with everolimus or sunitinib, first- (73:19) or second-line (sequential; 12:22) for progressive disease. Disease control rates (DCR: partial response or stable disease) at first-line were higher in all patients treated with everolimus than sunitinib (64/73 vs 12/19, P = 0.012). In PanNENs, DCR at first-line everolimus was 36/42 versus 9/15 with sunitinib (P = 0.062). Progression-free survival (PFS) at first-line everolimus was longer than sunitinib (31 months (95% CI: 23.1-38.9) vs 9 months (95% CI: 0-18.5); log-rank P < 0.0001) in the whole cohort and the subset of PanNENs (log-rank P < 0.0001). Median PFS at second-line MTT was 12 months with everolimus (95% CI: 4.1-19.9) vs 13 months with sunitinib (95% CI: 9.3-16.7; log-rank P = 0.951). Treatment with sunitinib (HR: 3.47; 95% CI: 1.5-8.3; P value: 0.005), KI67 >20% (HR: 6.38; 95% CI: 1.3-31.3; P = 0.022) and prior chemotherapy (HR: 2.71; 95% CI: 1.2-6.3; P = 0.021) were negative predictors for PFS at first line in multivariable and also confirmed at multi-state modelling analyses. Side effect (SE) analysis indicated events of serious toxicities (Grades 3 and 4: n = 13/85 for everolimus and n = 4/41 for sunitinib). Discontinuation rate due to SEs was 20/85 for everolimus versus 4/41 for sunitinib (P = 0.065). No additive toxicity of second-line MTT was confirmed. Based on these findings, and until reliable predictors of response become available, everolimus may be preferable to sunitinib when initiating MTT in progressive NENs.

SUBMITTER: Daskalakis K 

PROVIDER: S-EPMC6528409 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms.

Daskalakis Kosmas K   Tsoli Marina M   Angelousi Anna A   Kassi Evanthia E   Alexandraki Krystallenia I KI   Kolomodi Denise D   Kaltsas Gregory G   Koumarianou Anna A  

Endocrine connections 20190601 6


Comparisons between everolimus and sunitinib regarding their efficacy and safety in neuroendocrine neoplasms (NENs) are scarce. We retrospectively analysed the clinicopathological characteristics and outcomes in 92 patients with well-differentiated (WD) NEN of different origin (57 pancreatic NENs (PanNENs)), treated with molecular targeted therapy (MTT) with everolimus or sunitinib, first- (73:19) or second-line (sequential; 12:22) for progressive disease. Disease control rates (DCR: partial res  ...[more]

Similar Datasets

| S-EPMC4175512 | biostudies-literature
| S-EPMC8452477 | biostudies-literature
| S-EPMC4453618 | biostudies-literature
| S-EPMC10968806 | biostudies-literature
| S-EPMC4208619 | biostudies-literature
| S-EPMC8591206 | biostudies-literature
| S-EPMC5122404 | biostudies-literature
| S-EPMC7993001 | biostudies-literature
| S-EPMC5330615 | biostudies-literature
| S-EPMC6723560 | biostudies-literature